COBIMETINIB | COBIMETINIB | ATC L01EE02
ANTINEOPLASTIC TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION IN COMBINATION WITH VEMURAFENIB MAPK KINASE INHIBITOR MEK1 AND MEK2 INHIBITOR | ORAL | Cmax 514 NANOMOLAR Tmax 2.4 HOUR F 46 PERCENT VD 806 LITER PPB 95 PERCENT Cl 13.8 LITER / HOUR HT 44 HOUR | MAPK MEK1 MEK2 PDB 4AN2 (CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973), OR RELATED ANALOGS.) LIGAND CODE = EUI (link to the list of PDB complexes) Download experimental 3D coordinates of EUI with added hydrogens | Dual specificity mitogen-activated protein kinase kinase 1 UNIPROT Q02750 MAP2K1 more at DrugCentral | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |